Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.
Adverum Biotechnologies NASDAQ:
11/15/19 9:36 PM EST
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- Nov 7 2019
Summary ToggleAdverum Biotechnologies Reports Recent Business Progress and Third Quarter 2019 Financial Results
- Oct 31 2019
Summary ToggleAdverum Biotechnologies to Host a Conference Call and Webcast to Report Third Quarter 2019 Financial Results and Provide Corporate Updates
- Oct 30 2019
Summary ToggleAdverum Biotechnologies Expands Leadership Team with the Appointment of Peter Soparkar as Chief Legal Officer
- Oct 24 2019
Summary ToggleAdverum Biotechnologies Doses First Patient in Third Cohort of OPTIC Phase 1 Clinical Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD
There are currently no events to display.